Development and Implementation Strategies of a Nurse-led Symptom Self-management Program in Outpatient Cancer Centres: The Symptom Navi© Programme
Overview
Authors
Affiliations
Purpose: The Symptom Navi© Programme (SN©P) is a structured nurse-led intervention supporting symptom self-management in cancer patients. We describe the development and evaluation of the intervention, implementation strategy, and the evaluation of nurse training for the Symptom Navi© Pilot Study.
Methods: The intervention was developed using multiple methods (e.g. literature synthesis, focus groups) to produce SN©P information leaflets (SN©Flyers in French and German) and standardised training for nurses to deliver semi-structured consultations. We evaluated the SN©P using online surveys, focus groups, interviews, and the Item-Content Validity Index (I-CVI). Nurse training was evaluated in relation to content, acceptability, and confidence in implementing the SN©P. We examined the association between scored on the Work-related Sense of Coherence (Work-SoC) scale and nurses' confidence in implementing the SN©P. Thematic analysis was used to analyse qualitative data. Quantitative data was descriptively analysed and the Kendall Tau test was employed for correlations.
Results: Patients and health care professionals confirmed that SN©Flyers and semi-structured consultations facilitated symptom self-management. Nurses considered training content/format acceptable and appropriate and felt confident in implementing the SN©P. Overall Work-SoC scores were correlated with nurses' confidence in implementing the SN©P (r = .47, p = .04).
Conclusions: Health care professionals and cancer patients perceived the SN©P as a useful support. Successful implementation of the SN©P depends on centre-specific factors including time, resources and workflow.
Clinical Trial Registry: NCT03649984 and SNCTP000002381.
Tremblay D, Berbiche D, Roy M, Prady C, Durand M, Landry M Curr Oncol. 2024; 31(11):7287-7300.
PMID: 39590167 PMC: 11592751. DOI: 10.3390/curroncol31110537.
Kasgri K, Abazari M, Badeleh S, Badeleh K, Peyman N Cancer Control. 2024; 31:10732748241249355.
PMID: 38767653 PMC: 11107334. DOI: 10.1177/10732748241249355.
Arriola E, Jaal J, Edvardsen A, Silvoniemi M, Araujo A, Vikstrom A Oncologist. 2023; 29(4):e561-e569.
PMID: 38007400 PMC: 10994260. DOI: 10.1093/oncolo/oyad289.
Iivanainen S, Baird A, Balas B, Bustillos A, Castro Sanchez A, Eicher M BMJ Open. 2023; 13(4):e063242.
PMID: 37076159 PMC: 10124208. DOI: 10.1136/bmjopen-2022-063242.
Arditi C, Eicher M, Colomer-Lahiguera S, Bienvenu C, Anchisi S, Betticher D Eur J Cancer Care (Engl). 2022; 31(6):e13705.
PMID: 36130722 PMC: 9787424. DOI: 10.1111/ecc.13705.